<DOC>
	<DOCNO>NCT00647699</DOCNO>
	<brief_summary>Prospective , randomized multicenter study determine safety effectiveness perform cornea collagen cross-linking ( CXL ) use riboflavin UVA light eye progressive keratoconus .</brief_summary>
	<brief_title>Corneal Collagen Cross-linking Progressive Keratoconus</brief_title>
	<detailed_description>This sham control study first three month . Patients one eye designate study eye randomize receive one two study treatment ( CXL sham ) study eye . The patient evaluate 1 , 3 , 6 , 12 month . At month 3 later patient option receive CXL treatment sham non-study eye .</detailed_description>
	<mesh_term>Keratoconus</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Riboflavin</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis keratoconus Documented progression previous 24 month Decreased BSCVA Must complete study visit Prior corneal surgery Intacs History delay wound heal</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>keratoconus</keyword>
	<keyword>cross-linking</keyword>
	<keyword>riboflavin</keyword>
	<keyword>UVA light</keyword>
	<keyword>cornea</keyword>
</DOC>